Mefruside: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
Rabin Bista (talk | contribs) No edit summary |
||
(One intermediate revision by one other user not shown) | |||
Line 28: | Line 28: | ||
| routes_of_administration = Oral | | routes_of_administration = Oral | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
'''Mefruside''' ([[International Nonproprietary Name|INN]]) is a [[diuretic]] indicated for the treatment of edema and hypertension.<ref name="pmid4779251">{{cite journal |author=Allen HB, Lee DA |title=A general practice assessment of mefruside ('Baycaron') in the treatment of oedema and hypertension |journal=Curr Med Res Opin |volume=1 |issue=9 |pages=547–53 |year=1973 |pmid=4779251 |doi= |url=}}</ref> | '''Mefruside''' ([[International Nonproprietary Name|INN]]) is a [[diuretic]] indicated for the treatment of edema and hypertension.<ref name="pmid4779251">{{cite journal |author=Allen HB, Lee DA |title=A general practice assessment of mefruside ('Baycaron') in the treatment of oedema and hypertension |journal=Curr Med Res Opin |volume=1 |issue=9 |pages=547–53 |year=1973 |pmid=4779251 |doi= |url=}}</ref> | ||
Line 37: | Line 37: | ||
==References== | ==References== | ||
{{ | {{reflist|2}} | ||
[[Category:Diuretics]] | [[Category:Diuretics]] | ||
[[Category:Sulfonamides]] | [[Category:Sulfonamides]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
Latest revision as of 16:02, 15 April 2015
Clinical data | |
---|---|
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C13H19ClN2O5S2 |
Molar mass | 382.88 g/mol |
3D model (JSmol) | |
|
WikiDoc Resources for Mefruside |
Articles |
---|
Most recent articles on Mefruside |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mefruside at Clinical Trials.gov Clinical Trials on Mefruside at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mefruside
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mefruside Discussion groups on Mefruside Directions to Hospitals Treating Mefruside Risk calculators and risk factors for Mefruside
|
Healthcare Provider Resources |
Causes & Risk Factors for Mefruside |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mefruside (INN) is a diuretic indicated for the treatment of edema and hypertension.[1]
It was developed by Bayer A.G. and is sold under the tradename Baycaron.
References
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Diuretics
- Sulfonamides
- Cardiovascular Drugs
- Drug